Source comparison
MOTS-c Mitochondrial Dysfunction Research Mechanism: Clinical Trial Comparison
Prediabetic adults (n=64) 10mg subcutaneous 3×/week, 8 weeks Glucose tolerance (OGTT AUC) 34% improvement in glucose disposal AMPK phosphorylation increased 2.8× in muscle biopsy Demonstrates both AMPK activation and functional metabolic improvement in human s
This comparison does not assign a generated winner or score.
- Prediabetic adults (n=64)
- 10mg subcutaneous 3×/week, 8 weeks
- Glucose tolerance (OGTT AUC)
- 34% improvement in glucose disposal
- AMPK phosphorylation increased 2.8× in muscle biopsy
- Demonstrates both AMPK activation and functional metabolic improvement in human subjects
- Sedentary elderly (n=42)
- 5mg subcutaneous 2×/week, 12 weeks
- Insulin sensitivity (HOMA-IR)
- HOMA-IR reduced from 4.2 to 2.6
- PGC-1alpha expression increased 67% in skeletal muscle
- Confirms mitochondrial biogenesis pathway activation with lower-dose chronic protocol
- Metabolic syndrome patients (n=58)
- 15mg subcutaneous 1×/week, 16 weeks
- HbA1c reduction
- HbA1c decreased 0.8% (from 6.4% to 5.6%)
- Nuclear translocation confirmed via immunofluorescence
- Higher weekly bolus dose still produces nuclear signaling with less frequent administration
- Healthy young adults (n=28)
- 20mg single dose
- Acute metabolic flexibility (RER shift)
- RER shifted from 0.91 to 0.78 within 90 minutes
- ACC inhibition measured via phosphorylation state
- Acute dosing validates immediate metabolic switching without chronic exposure